Page 25 - Pharma Intelligence News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligence’s 2020 Pulse Report when the COVID-19 vaccines had yet to be made available in the United States. 1 In fact, the percentage of Americans saying they’d be more likely to take a COVID-19 vaccine if they had more information on the clinical trials has dropped by half since 2020 (14% from 28%). Furthermore, the number of Americans saying they’d be more likely to participate in a clinical tri...

Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligence’s 2020 Pulse Report when the COVID-19 vaccines had yet to be made available in the United States. 1 In fact, the percentage of Americans saying they’d be more likely to take a COVID-19 vaccine if they had more information on the clinical trials has dropped by half since 2020 (14% from 28%). Furthermore, the number of Americans saying they’d be more likely to participate in a clinical tri...

Informa Business Intelligence: While Over Three-Quarters of Americans Are Willing to Take at Least One of the Authorized COVID-19 Vaccines, Nearly a Quarter Are Still Hesitant as the U.S. Changes Course on Mitigation Strategy Understanding of Clinical Trials Up Among Americans Although vaccine hesitancy remains, levels of understanding have improved nearly two-fold following sentiments captured in Informa Pharma Intelligence's 2020 Pulse Reportwhen the COVID-19 vaccines had yet to be made available in the United States. 1 In fact, the percentage of Americans saying they'd be more likely to ta...

Deep Pharma Intelligence released a special 115-page analytical report Cell Therapies In Healthcare Landscape Overview 2021 (Stem Cells and CAR-Ts), which is

Author Bio Rachel primarily covers healthcare stocks for the Fool. She leverages her background and education in the legal field to inform her detailed research and analysis of the stock market. It's a remarkable time to be an investor. Over the past year, the market has not only recovered its losses from the coronavirus crash, but marked multiple days of new thrilling highs. The stock market has shown increased volatility in recent weeks. But for the time being, optimism about the U.S. economy's ongoing recovery is outweighing investor concern about the rising rate of...